CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients

Recent years have witnessed the groundbreaking success of immune checkpoint blockage (ICB) in metastasized malignant melanoma. However, biomarkers predicting the response to ICB are still urgently needed. In the present study, we investigated CTLA4 promoter methylation (mCTLA4) in 470 malignant mela...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Goltz, Diane, Gevensleben, Heidrun, Vogt, Timo J., Dietrich, Joern, Golletz, Carsten, Bootz, Friedrich, Kristiansen, Glen, Landsberg, Jennifer, Dietrich, Dimo
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6124533/
https://ncbi.nlm.nih.gov/pubmed/29997292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados